AA
ALXO icon

ALPS Advisors’s ALX Oncology ALXO Stock Holding History

ALPS Advisors’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-30,358
Closed -$146K – 965
2023
Q3 		$146K Buy
30,358
+317
+1% +$1.72K ﹤0.01% 965
2023
Q2 		$226K Buy
30,041
+3,191
+12% +$20.9K ﹤0.01% 971
2023
Q1 		$121K Sell
26,850
-853
-3% -$6.46K ﹤0.01% 995
2022
Q4 		$312K Buy
27,703
+5,449
+24% +$61.2K ﹤0.01% 847
2022
Q3 		$213K Sell
22,254
-1,876
-8% -$21.9K ﹤0.01% 998
2022
Q2 		$195K Sell
24,130
-17,634
-42% -$192K ﹤0.01% 998
2022
Q1 		$706K Sell
41,764
-5,108
-11% -$87.2K 0.01% 350
2021
Q4 		$1.01M Sell
46,872
-2,576
-5% -$111K 0.01% 358
2021
Q3 		$3.65M Sell
49,448
-3,234
-6% -$216K 0.04% 196
2021
Q2 		$2.88M Buy
+52,682
New +$3.15M 0.03% 223

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

ALPS Advisors's ALXO Position: Q4 2023 in Review

ALPS Advisors sold out of ALX Oncology (ALXO) in Q4 2023, closing a stake of 30,358 shares — an estimated $146K sold.

ALPS Advisors first reported a position in ALXO in Q2 2021 and held it in 10 quarters. The position peaked at $3.65M in Q3 2021. 93 funds tracked by Wall St. Rank hold ALXO as of Q4 2023.

  • ALPS Advisors reported no remaining ALX Oncology position as of Q4 2023 after selling out during the quarter.
  • ALPS Advisors sold 30,358 ALX Oncology shares in Q4 2023, an estimated $146K.
  • ALPS Advisors first reported a position in ALX Oncology in Q2 2021 and held it in 10 quarters.
  • ALPS Advisors's ALX Oncology position peaked at $3.65M in Q3 2021.
  • 93 funds tracked by Wall St. Rank held ALX Oncology as of Q4 2023.

Based on ALPS Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.